Abstract
Recently, the correlation between the efficacy of platinum-based chemotherapy and ERCC1 expression in patients with SCLC has attracted wide-spread attention, and a lot of investigations have been conducted, whereas conflicting results were presented. Therefore, we performed the present meta-analysis of eligible studies to derive a more precise evaluation of the association between ERCC1 expression and the clinical outcome in SCLC patients receiving platinum-based chemotherapy. A literature search for relevant studies was conducted in the electronic databases of PubMed, EMBASE and Web of Science. The inclusive criteria were SCLC patients treated by platinum-based chemotherapy, and evaluated the relationship between ERCC1 expression and the clinical outcomes [including overall response rate (ORR), overall survival (OS) or progression-free survival (PFS)]. Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) was calculated to assess the risk. A total of nine studies including 1129 patients were included in final analysis. Our analysis indicated that positive/high ERCC1 expression was associated with unfavorable OS (HR = 1.18, 95%CI = 1.02–1.37) and PFS (HR = 1.46, 95%CI = 1.14–1.88). Subgroup analysis according to disease stage suggested the significant relationship was found in limited stage (LS-SCLC), but not in extensive stage (ES-SCLC). However, no significant association was found between ERCC1 expression and ORR. Our analysis suggested ERCC1 expression may be a prognostic factor in SCLC patients receiving platinum-based chemotherapy, especially for LS-SCLC.
Highlights
Lung cancer is a common malignancy and has been a leading cause of mortality and a burden of health finance cost worldwide [1]
The hazard ratios (HRs) and their corresponding 95% confidence interval (CI) were used to evaluate the relationship between Excision Repair Cross-Complementation Group 1 (ERCC1) expression and overall survival (OS) and progression-free survival (PFS) in small cell lung cancer (SCLC) patients treated by platinum-based chemotherapy
In the present meta-analysis, our analysis indicated that SCLC patients with positive/high ERCC1 expression were significantly associated with shorter OS and PFS, especially in limited stage (LS)-SCLC
Summary
Lung cancer is a common malignancy and has been a leading cause of mortality and a burden of health finance cost worldwide [1]. It has been reported by the International Agency for Research on Cancer for 2008 that a total of 1.6 million individuals were diagnosed as lung cancer and approximately 1.4 million died from the disease, making it the first leading cause of cancer mortality in men and second in women throughout the world [2]. Most of the SCLC cases (70%–80%) are diagnosed at an extensive stage (ES-SCLC) and only a small number of SCLC patients are found to be limited to the thorax (LS-SCLC) [7]. A growing number of evidence suggests that biological markers may contribute greatly to the efficacy of chemotherapy; ERCC1 is one of the most notable biomarkers among them
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
